Proteolysis targeting chimeras in non-small cell lung cancer

Garo Hagopian; Christopher Grant; Misako Nagasaka

doi:10.1016/j.ctrv.2023.102561

Proteolysis targeting chimeras in non-small cell lung cancer

Cancer Treat Rev. 2023 Jun:117:102561. doi: 10.1016/j.ctrv.2023.102561. Epub 2023 Apr 26.

Authors

Garo Hagopian¹, Christopher Grant¹, Misako Nagasaka²

Affiliations

¹ Department of Medicine, University of California Irvine Medical Center, Orange CA, United States.
² Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, CA, United States; St. Marianna University School of Medicine, Kawasaki, JAPAN. Electronic address: nagasakm@hs.uci.edu.

PMID: 37178629
DOI: 10.1016/j.ctrv.2023.102561

Abstract

Non-small cell lung cancer (NSCLC) has very poor prognosis in advanced stages. Discovery and application of therapies targeting specific oncogenic driver mutations has greatly improved overall survival. However, targeted therapies are limited in their efficacy due to resistance mutations that may arise with long term use. Proteolysis targeting Chimeras (PROTACs) are a promising approach to combating resistance mutations. PROTACs commandeer innate ubiquitination machinery to degrade oncogenic proteins. Here we review the PROTACs that have been developed for targeting common EGFR, KRAS, and ALK mutations.

Keywords: ALK; EGFR; KRAS; PROTACs; Targeted therapy.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Prognosis
Proteolysis Targeting Chimera

Substances

Proteolysis Targeting Chimera